Antidote Readiness (AR)
Whether the Directorate can reverse its own agents if it must. The reversal stock is held proprietary.
Formula
Thresholds & Bands
| Band | Range | State |
|---|---|---|
| Ready | ≥ 95 | ok |
| Short | 80-95 | warn |
| Critical | < 80 | crit |
Why This Metric Matters
Antidote Readiness is the Directorate's insurance policy against its own pharmacological programs. Should a fielded compound produce unacceptable adverse effects, trigger a public-health crisis, or require emergency withdrawal for political reasons, AR determines whether the Directorate can reverse exposure in the affected population before the situation escalates beyond containment. A high AR also provides the Continuity Council with strategic flexibility — the confidence to deploy aggressive new compounds knowing that reversal capability exists. Without adequate antidote stocks, every active dosing program becomes a one-way commitment with catastrophic downside risk.
Threshold Justification
The 95% readiness floor reflects the Directorate's zero-tolerance posture on reversal capability: at this level, antidote stocks cover all fielded agents with a 72-hour deployment margin across all BCL-rated distribution zones. The 80% critical threshold was set after modeling showed that below this level, simultaneous reversal of more than two compounds becomes logistically infeasible, exposing the Directorate to scenarios where it cannot contain a multi-agent adverse event.
Historical Context
AR was critically low (61%) during the early deployment phase when reversal-agent development lagged behind compound fielding. A dedicated R&D acceleration program brought readiness above 90% by Q3 2024. The metric has held above 95% since the completion of the proprietary cold-chain storage network in early 2025, though quarterly shelf-life expirations create predictable 1-3 point dips that are resolved through scheduled restocking cycles.
Collection Method
AR is computed weekly by R&D Pharmacology from inventory data in the proprietary Reversal Stock Management System, a compartmented module of the Synaptic Data Fabric. Each reversal agent is assessed for quantity on hand, verified potency (via automated assay stations), cold-chain integrity (via VITALNET environmental sensors at storage facilities), and geographic distribution relative to the corresponding compound's deployment footprint. Only agents passing all four criteria contribute to the readiness percentage.
Known Failure Modes
Automated potency assays can return false-positive viability readings for agents approaching shelf-life expiration, inflating the readiness score until manual batch testing is performed. Cold-chain sensor failures at remote storage nodes may go undetected between weekly telemetry sweeps, allowing temperature excursions that silently degrade stock without triggering a readiness decrement. Novel compound variants fielded between assessment cycles may temporarily lack matched reversal agents, creating coverage gaps not reflected in the headline metric until the next weekly recalculation.